Pfizer Races to Save Obesity Drugmaker Deal After Novo’s Bid

Pfizer Inc. has four days.

Danish drugmaker Novo Nordisk A/S upended the US pharma giant’s deal to acquire obesity upstart Metsera Inc. Thursday morning with a rival bid that caused Metsera’s shares to surge more than 25%. Now Pfizer — which was one of seven bidders for the company before striking a deal in September for about $5 billion — has a very short window to trump Novo’s bid or walk away.